NEUP
Neuphoria Therapeutics Inc.
Key Financials
Net Income
$-369632
↑ 97.6%
Revenue
$15.6M
N/A
Operating Income
$-1129091
↑ 93.7%
Total Assets
$28.6M
↑ 3.4%
Total Liabilities
$9.6M
↓ 5.6%
EPS (Diluted)
$-0.23
↓ 2200.0%
Shareholders' Equity
$19.0M
↑ 8.6%
Cash & Equivalents
$14.2M
↑ 12.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/26/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 10-Q | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/6/2026 | View on SEC |
| 4 | 1/21/2026 | View on SEC |
| 4 | 1/21/2026 | View on SEC |
| 4 | 1/21/2026 | View on SEC |
| 4 | 1/21/2026 | View on SEC |
| 8-K | 1/8/2026 | View on SEC |
| SCHEDULE 13D/A | 12/29/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NEUP |
| Company Name | Neuphoria Therapeutics Inc. |
| CIK | 1191070 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | C3 |
| Phone | 781-439-5551 |